Imidazo [1, 2-a] pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors
…, JD Culshaw, S Green, SE Oakes, AP Thomas
Index: Byth, Kate F.; Culshaw, Janet D.; Green, Stephen; Oakes, Sandra E.; Thomas, Andrew P. Bioorganic and Medicinal Chemistry Letters, 2004 , vol. 14, # 9 p. 2245 - 2248
Full Text: HTML
Citation Number: 94
Abstract
Exploration of SAR and optimisation of the imidazo [1, 2-a] pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions of substitution, which allow modification of physical properties and offer the potential for in vivo optimisation.
Related Articles:
[Alam, Mahbub; Beevers, Rebekah E.; Ceska, Tom; Davenport, Richard J.; Dickson, Karen M.; Fortunato, Mara; Gowers, Lewis; Haughan, Alan F.; James, Lynwen A.; Jones, Mark W.; Kinsella, Natasha; Lowe, Christopher; Meissner, Johannes W.G.; Nicolas, Anne-Lise; Perry, Benjamin G.; Phillips, David J.; Pitt, William R.; Platt, Adam; Ratcliffe, Andrew J.; Sharpe, Andrew; Tait, Laura J. Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 12 p. 3463 - 3467]
[Ducray, Richard; Boutron, Pascal; Didelot, Myriam; Germain, Herve; Lach, Franck; Lamorlette, Maryannick; Legriffon, Antoine; Maudet, Mickael; Menard, Morgan; Pasquet, Georges; Renaud, Fabrice; Simpson, Iain; Young, Gail L. Tetrahedron Letters, 2010 , vol. 51, # 36 p. 4755 - 4758]
[Ducray, Richard; Jones, Clifford D.; Jung, Frederic H.; Simpson, Iain; Curwen, Jon; Pass, Martin Bioorganic and Medicinal Chemistry Letters, 2011 , vol. 21, # 16 p. 4702 - 4704]